Edotreotide

Summary

Edotreotide is a radiolabeled somatostatin analogue used in peptide receptor radionuclide therapy (PRRT) for advanced, somatostatin‑receptor‑positive neuroendocrine tumours (NETs), especially gastro‑enteropancreatic (GEP) NETs. The drug is administered intravenously as a Lu‑177‑edotreotide complex and delivers targeted beta‑radiation to tumour cells, aiming to halt disease progression and improve survival.

Mechanism of Action

Edotreotide consists of a somatostatin‑analogue peptide (DOTATOC) that binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is over‑expressed on many NET cells. After receptor binding, the peptide‑radioisotope conjugate is internalised, bringing the beta‑emitting radionuclide Lu‑177 into the tumour cell. The emitted beta particles cause DNA double‑strand breaks and cytotoxicity, while the short‑range radiation spares most surrounding normal tissue.

What the Research Shows

A phase‑3, open‑label COMPETE trial compared Lu‑177‑edotreotide with oral everolimus in 324 patients with progressive, SSTR‑positive GEP‑NETs. Lu‑177‑edotreotide achieved a median progression‑free survival of 23.9 months versus 14.1 months for everolimus (hazard ratio 0.67, p=0.022). Treatment‑related adverse events occurred in 82% of the PRRT group, with grade 3‑4 events in 18%, compared with 97% and 40% respectively for everolimus. No treatment‑related deaths were reported. A systematic review and meta‑analysis of eight studies (n≈400 patients) found objective response rates of 34% in GEP‑NETs (19% overall), disease‑control rates of 78% (GEP) and median overall survival around 45 months, while grade 3‑4 toxicities were infrequent. A 2022 review highlighted low overall toxicity, a 1.8% incidence of secondary malignancies, and the potential to expand PRRT to neoadjuvant or rechallenge settings.

Reported Benefits

Lu‑177‑edotreotide provides a statistically significant extension of progression‑free survival compared with standard targeted therapy, with median PFS gains of roughly 10 months. Objective response rates in GEP‑NETs approach one‑third of treated patients, and disease‑control rates exceed three‑quarters, indicating durable tumour stabilisation. The safety profile is generally favourable, with most adverse events being mild (diarrhoea, nausea, asthenia) and serious toxicities occurring less frequently than with everolimus. These attributes support its use early in the treatment algorithm for advanced NETs.

Limitations of the Evidence

Evidence is largely confined to advanced, SSTR‑positive NETs; data in earlier‑stage disease or non‑GEP NETs remain limited. The meta‑analysis reported high heterogeneity, reflecting variability in patient populations and study designs, which tempers confidence in pooled efficacy estimates. Long‑term outcomes, including the risk of secondary malignancies, are based on limited follow‑up. Comparative data are primarily versus everolimus; head‑to‑head trials against other PRRT agents or newer systemic therapies are lacking. Predictive biomarkers beyond receptor imaging have not been established.

Safety Considerations

The most common treatment‑related adverse events are diarrhoea, nausea and asthenia, occurring in about one‑third of patients. Grade 3‑4 toxicities are reported in roughly 18% of recipients, with haematologic effects (e.g., anaemia, thrombocytopenia) being the most serious, though no treatment‑related deaths have been observed. Long‑term safety data suggest a low but measurable risk (≈1.8%) of secondary malignancies. Caution is advised in patients with impaired renal function or bone‑marrow reserve, and routine monitoring of blood counts and kidney parameters is recommended during and after therapy.

How It Is Administered

Edotreotide is supplied as a radiopharmaceutical solution of Lu‑177‑edotreotide. It is administered by intravenous infusion in a nuclear‑medicine setting, typically at a dose of about 7.5 GBq every three months, for up to four cycles, depending on individual response and tolerability. The preparation requires specialized handling due to radioactivity, and patients are observed for acute reactions post‑infusion.

Routes of Administration

Goals & Uses

• Tumor detectionDiagnostic ImagingModerate
• Detection of paraganglioma and pheochromocytomaDiagnostic / ImagingModerate
• PET imaging of somatostatin receptor-positive neuroendocrine tumorsDiagnostic / ImagingHigh
• Peptide receptor radionuclide therapy (PRRT) of NETsOncology / TherapyModerate
• Tumor staging and restaging of neuroendocrine tumorsDiagnostic / ImagingHigh

Contraindications

• Hypersensitivity to somatostatin analogues or indium‑111 compoundsAllergyHigh
• Severe renal impairment (for 90Y-DOTATOC therapy)Organ ImpairmentHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
• Hypersensitivity to edotreotide or somatostatin analoguesAllergy / HypersensitivityHigh

Adverse Effects

• Radiation exposureRadiologicalUnknown
• Injection site reactionsLocalUncommon
• Radiation-induced secondary malignancyOncologicRare
• FlushingVascularCommonWarmth and redness of the skin
• Nausea and vomitingGastrointestinalCommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• MyelosuppressionHematologicUncommon
• Transient hormonal effects (hypoglycemia, flushing)EndocrineUncommon
• NephrotoxicityRenalUncommon

Drug Interactions

• Chemotherapy agents causing myelosuppressionModerate
• Long-acting somatostatin analogues (octreotide LAR, lanreotide)Moderate
• Other radiopharmaceuticalsModerate
• Nephrotoxic agents (aminoglycosides, NSAIDs, cisplatin)High

Population Constraints

• Patients with bone marrow compromiseHematologicRelative
• Pediatric patientsAgeRelative
• Patients with renal impairmentOrgan ImpairmentRelative
• Elderly patientsAgeRelative
• Pregnant womenReproductiveAbsolute

Regulatory Status

• European UnionUnapprovedNo marketing authorization; limited clinical trial use.
• United StatesInvestigationalUsed under IND for diagnostic SPECT imaging.
• United KingdomApprovedApproved: PET imaging of somatostatin receptor-positive NETs (SomaKit TOC, post-Brexit recognition of EMA approval)Recognized following EMA approval; MHRA status aligns with EU for SomaKit TOC.

Not FDA‑approved; used under investigational new drug (IND) protocols for diagnostic imaging. No commercial brand in the US.

Evidence & Sources

• [(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial
  Journal ArticleModerateWalter T, et al.2026-01-01T00:00:00.000000Z
• New Insights in PRRT: Lessons From 2021
  Journal ArticleModeratePuliani G, et al.2022-01-01T00:00:00.000000Z
• Systematic review and meta-analysis of the efficacy and safety of [(177)Lu]Lu-edotreotide ([(177)Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors
  Journal ArticleHighBaum RP, et al.2026-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleModerateBayes M, Rabasseda X, Prous JR2006-01-01T00:00:00.000000Z
• Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?
  Journal ArticleModerateLa Salvia A, et al.2021-01-01T00:00:00.000000Z

Frequently Asked Questions